Synthetic cannabinoid-induced psychotic disorder (Q40316): Difference between revisions

From determinar.ia.br - Determine suas informações
‎Created a new Item
 
‎Changed an Item
 
(7 intermediate revisions by the same user not shown)
description / pt-brdescription / pt-br
 
Transtorno psicótico induzido por canabinoides sintéticos é caracterizado por sintomas psicóticos (p. ex., delírios, alucinações, pensamento desorganizado, comportamento grosseiramente desorganizado) que se desenvolvem durante ou logo após intoxicação por ou abstinência de canabinoides sintéticos. A intensidade ou duração dos sintomas é consideravelmente maior do que alterações de percepção, cognição ou comportamento do tipo psicótico que são características de intoxicação por canabinoides sintéticos ou abstinência de canabinoides sintéticos. A quantidade e duração do uso de canabinoides sintéticos devem ser capazes de produzir sintomas psicóticos. Os sintomas não são mais bem explicados por um transtorno mental primário (p. ex., esquizofrenia, transtorno do humor com sintomas psicóticos), como pode ser o caso se os sintomas psicóticos precederam o início do uso de canabinoides sintéticos, se os sintomas persistem por um período de tempo considerável após a cessação do uso ou abstinência de canabinoides sintéticos, ou se há outra evidência de um transtorno mental primário com sintomas psicóticos pré-existente (p. ex., história de episódios anteriores não associados ao uso de canabinoides sintéticos).
description / endescription / en
 
Synthetic cannabinoid-induced psychotic disorder is characterised by psychotic symptoms (e.g., delusions, hallucinations, disorganised thinking, grossly disorganised behaviour) that develop during or soon after intoxication with or withdrawal from synthetic cannabinoids. The intensity or duration of the symptoms is substantially in excess of psychotic-like disturbances of perception, cognition, or behaviour that are characteristic of Synthetic cannabinoid intoxication or Synthetic cannabinoid withdrawal. The amount and duration of synthetic cannabinoid use must be capable of producing psychotic symptoms. The symptoms are not better explained by a primary mental disorder (e.g., Schizophrenia, a Mood disorder with psychotic symptoms), as might be the case if the psychotic symptoms preceded the onset of the synthetic cannabinoid use, if the symptoms persist for a substantial period of time after cessation of the synthetic cannabinoid use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with psychotic symptoms (e.g., a history of prior episodes not associated with synthetic cannabinoid use).
Property / Canonical URI
 
Property / Canonical URI: https://id.who.int/icd/entity/1995589534 / rank
 
Normal rank
Property / CURIE
 
CID11:6C42.6
Property / CURIE: CID11:6C42.6 / rank
 
Normal rank
Property / Canary Token
 
dki-india-6C42.6
Property / Canary Token: dki-india-6C42.6 / rank
 
Normal rank
Property / Verification Status
 
Concluído
Property / Verification Status: Concluído / rank
 
Normal rank
Property / Knowledge Architect
 
Property / Knowledge Architect: https://pauloleads.com.br/cases-publicos/ / rank
 
Normal rank
Property / Collection date
 
13 August 2026
Timestamp+2026-08-13T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
Property / Collection date: 13 August 2026 / rank
 
Normal rank
Property / Linked ICD 10
 
Property / Linked ICD 10: F12 / rank
 
Normal rank

Latest revision as of 06:04, 13 August 2026

Synthetic cannabinoid-induced psychotic disorder is characterised by psychotic symptoms (e.g., delusions, hallucinations, disorganised thinking, grossly disorganised behaviour) that develop during or soon after intoxication with or withdrawal from synthetic cannabinoids. The intensity or duration of the symptoms is substantially in excess of psychotic-like disturbances of perception, cognition, or behaviour that are characteristic of Synthetic cannabinoid intoxication or Synthetic cannabinoid withdrawal. The amount and duration of synthetic cannabinoid use must be capable of producing psychotic symptoms. The symptoms are not better explained by a primary mental disorder (e.g., Schizophrenia, a Mood disorder with psychotic symptoms), as might be the case if the psychotic symptoms preceded the onset of the synthetic cannabinoid use, if the symptoms persist for a substantial period of time after cessation of the synthetic cannabinoid use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with psychotic symptoms (e.g., a history of prior episodes not associated with synthetic cannabinoid use).
Language Label Description Also known as
default for all languages
6C42.6
    English
    Synthetic cannabinoid-induced psychotic disorder
    Synthetic cannabinoid-induced psychotic disorder is characterised by psychotic symptoms (e.g., delusions, hallucinations, disorganised thinking, grossly disorganised behaviour) that develop during or soon after intoxication with or withdrawal from synthetic cannabinoids. The intensity or duration of the symptoms is substantially in excess of psychotic-like disturbances of perception, cognition, or behaviour that are characteristic of Synthetic cannabinoid intoxication or Synthetic cannabinoid withdrawal. The amount and duration of synthetic cannabinoid use must be capable of producing psychotic symptoms. The symptoms are not better explained by a primary mental disorder (e.g., Schizophrenia, a Mood disorder with psychotic symptoms), as might be the case if the psychotic symptoms preceded the onset of the synthetic cannabinoid use, if the symptoms persist for a substantial period of time after cessation of the synthetic cannabinoid use or withdrawal, or if there is other evidence of a pre-existing primary mental disorder with psychotic symptoms (e.g., a history of prior episodes not associated with synthetic cannabinoid use).

      Statements

      CID11:6C42.6
      0 references
      dki-india-6C42.6
      0 references
      Concluído
      0 references
      13 August 2026
      0 references
      0 references